When did Kyverna Therapeutics, Inc. report Q4 2024 earnings?

Kyverna Therapeutics, Inc. (KYTX) reported Q4 2024 earnings on March 27, 2025 before market open.

What were Kyverna Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Kyverna Therapeutics, Inc. reported diluted EPS of $-0.88 for Q4 2024.

Did Kyverna Therapeutics, Inc. beat estimates in Q4 2024?

EPS missed the consensus estimate of $-0.87 by $0.01.

Where can I find Kyverna Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-046074) directly on SEC EDGAR. The filing index links above go to sec.gov.

Kyverna Therapeutics, Inc. KYTX Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

Diluted EPS-$0.88Miss by $0.01

EPS estimate-$0.87

Next report

Aug 11, 2026 (In 4 weeks)

EPS estimate-$0.67

Financials

Q4 2024

Income statement

See full

Operating income-$41.0M-92.0%

Net income-$37.5M-81.4%

EPS (diluted)-$0.88+96.7%

Balance sheet

See full

Cash & equivalents$96.6M+179%

Total debt$9.0M-0.6%

Total equity$266.6M+2,129%

Total assets$304.6M+305%

Cash flow

See full

Operating cash flow-$37.1M-99.6%

CapEx$532.0K+59.3%

Free cash flow-$37.6M-98.9%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$161.46M—

Enterprise value$73.86M—

Returns & leverage

See full

Debt / equity0×—

Current ratio8.6×+5.6×

Versus estimates

Diluted EPS

Q1 2026-$0.66Beat by $0.09 Q4 2025-$0.80Beat by $0.04 Q3 2025-$0.85Beat by $0.12 Q2 2025-$0.97Beat by $0.03 Q1 2025-$1.03Beat by $0.18

Q4 2024-$0.88Miss by $0.01

Ask the moment Kyverna Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Kyverna Therapeutics, Inc. report Q4 2024 earnings?: Kyverna Therapeutics, Inc. (KYTX) reported Q4 2024 earnings on March 27, 2025 before market open.
What were Kyverna Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Kyverna Therapeutics, Inc. reported diluted EPS of $-0.88 for Q4 2024.
Did Kyverna Therapeutics, Inc. beat estimates in Q4 2024?: EPS missed the consensus estimate of $-0.87 by $0.01.
Where can I find Kyverna Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-046074) directly on SEC EDGAR. The filing index links above go to sec.gov.